Table 2.
Analysis of the 252 patients with inclusion body myositis compared to 1,008 ethnically matched controlsa
| Gene region | Chr. | Position | SNP | Minor allele | MAF in patients | MAF in controls | P | OR (95% CI) |
Localization of LD to nearest genes (r2 ≥ 0.9) |
|---|---|---|---|---|---|---|---|---|---|
| MHC | 6 | 32358201 | rs3129950 | C | 0.34 | 0.11 | 3.58 × 10−33 b | 5.69 (4.28–7.55) | MHC |
| CCR3/CCR2 | 3 | 46389462 | rs112088397 | T | 0.08 | 0.16 | 1.93 × 10−6 c | 0.42 (0.29–0.60) | Downstream of CCR3 to intron 2 of LTF; incorporating CCR2, CCR5, and CCRL2 |
| FLJ14816/GLI2 | 2 | 121338584 | rs1880542 | T | 0.56 | 0.45 | 5.66 × 10−6 c | 1.60 (1.31–1.96) | Intergenic of FLJ14816 and GLI2 |
| LOC100128517/LOC728961 | 6 | 14560180 | rs9396510 | T | 0.11 | 0.05 | 7.52 × 10−6 c | 2.23 (1.57–3.17) | Intergenic of LOC100128517 and LOC728961 |
a
Coordinates are based on the human assembly GRCh37. Chr. = chromosome; SNP = single‐nucleotide polymorphism; MAF = minor allele frequency; OR = odds ratio; 95% CI = 95% confidence interval; LD = linkage disequilibrium.
b
Reported at genome‐wide significance (P < 5 × 10−8).
c
Reported at second tier of significance (P < 2.25 × 10−5).